Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
来自MSN28 天
Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer
CheckMate -8HW enrolled patients with colorectal cancer whose tumors were characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic.
The American Journal of Managed Care16 天
Patients With Colorectal Cancer Seek More Say in Treatment, Face Financial Barriers
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, discusses a study conducted with Takeda and the Harris Poll, focusing on the treatment experiences of patients with metastatic ...
MedPage Today1 个月
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
We need a much larger study." In her introductory comments, Geng agreed with Kunz's assessment that unresectable locally advanced/metastatic G/GEJ cancer has a poor prognosis, and chemotherapy is ...
Targeted Oncology4 天
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
FiercePharma28 天
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
In BMS’ case, the company’s dual immunotherapy of Opdivo and Yervoy showed it could work better than Opdivo alone in patients with certain metastatic colorectal cancer. The combo lowered the ...